Zoom: What did you mean by that last sentence abou
Post# of 30028
I would suspect that would be our first MANF partnership. But we will not begin doing a clincial trial on any MANF indication until the end of 2015 or beginning of 2016. That is 12 to 18 months away. That is why I am not counting on a MANF partnership this year.
We might get an orphan designation by Q4 this year, but that will only pop up our stock a bit, in my opinion. MANF/Retinitis is more valuable than even Lympro, so why would Gerald give that away to a partner unless that partner paid through the nose? And why would a BP pay through the nose on a pre-clinical drug 12 to 18 months away from it's first clinical trials?
It could happen in the next 3 to 6 months, but I'm not counting on it. I'd be interested in knowing what this patient heard.